Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel
N Raje, K Anderson, H Einsele, Y Efebera, F Gay… - Blood cancer …, 2023 - nature.com
Bispecific antibodies (BsAbs) are emerging as an important novel class of
immunotherapeutic agents for the treatment of multiple myeloma (MM), and are set to be …
immunotherapeutic agents for the treatment of multiple myeloma (MM), and are set to be …
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European …
T-cell redirecting bispecific antibodies (BsAbs) and chimeric antigen receptor T cells (CAR T
cells) have revolutionised multiple myeloma therapy, but adverse events such as cytokine …
cells) have revolutionised multiple myeloma therapy, but adverse events such as cytokine …
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Elranatamab is a humanized B-cell maturation antigen (BCMA)-CD3 bispecific antibody. In
the ongoing phase 2 MagnetisMM-3 trial, patients with relapsed or refractory multiple …
the ongoing phase 2 MagnetisMM-3 trial, patients with relapsed or refractory multiple …
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management
SV Rajkumar - American journal of hematology, 2022 - Wiley Online Library
Abstract Disease Overview Multiple myeloma accounts for approximately 10% of
hematologic malignancies. Diagnosis The diagnosis requires≥ 10% clonal bone marrow …
hematologic malignancies. Diagnosis The diagnosis requires≥ 10% clonal bone marrow …
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial
Multiple myeloma (MM) is a plasma cell malignancy expressing B cell maturation antigen
(BCMA). Elranatamab, a bispecific antibody, engages BCMA on MM and CD3 on T cells …
(BCMA). Elranatamab, a bispecific antibody, engages BCMA on MM and CD3 on T cells …
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
In the post-pandemic COVID-19 period, human activities have returned to normal and
COVID-19 cases are usually mild. However, patients with multiple myeloma (MM) present an …
COVID-19 cases are usually mild. However, patients with multiple myeloma (MM) present an …
Recommendations on prevention of infections during chimeric antigen receptor T‐cell and bispecific antibody therapy in multiple myeloma
Chimeric antigen receptor T (CAR T) cell and bispecific antibody therapies have shown
unprecedented efficacy in heavily pretreated patients with multiple myeloma (MM). However …
unprecedented efficacy in heavily pretreated patients with multiple myeloma (MM). However …
Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study
CANDOR (NCT03158688) is a phase 3, randomized, open-label trial comparing carfilzomib,
daratumumab, and dexamethasone (KdD) vs carfilzomib and dexamethasone (Kd) in adults …
daratumumab, and dexamethasone (KdD) vs carfilzomib and dexamethasone (Kd) in adults …
Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC‐1 study
Background Patients with relapsed/refractory multiple myeloma are at increased risk of
infection. Infections during treatment with teclistamab, the first B‐cell maturation antigen …
infection. Infections during treatment with teclistamab, the first B‐cell maturation antigen …
Toxicity profile of chimeric antigen receptor T-cell and bispecific antibody therapies in multiple myeloma: pathogenesis, prevention and management
Multiple myeloma is the second-most common hematologic malignancy in adults worldwide.
Despite ongoing advancement in therapeutic modalities, it remains an incurable disease …
Despite ongoing advancement in therapeutic modalities, it remains an incurable disease …